TerSera Therapeutics
TerSera is a US specialty company whose oncology and supportive-care products include goserelin (Zoladex), rolapitant (Varubi) and telotristat ethyl (Xermelo) in the US.
Overview
TerSera acquired Zoladex US rights from AstraZeneca in 2017, Varubi from Tesaro in 2018 and Xermelo from Lexicon in 2020, building a portfolio of hormonal therapy and supportive-care products.
Scorecard
All companies- approved products +12
- modalities +2
- regions +2
- registry trials +8
Rolapitant (Varubi) is a long-lasting anti-sickness tablet taken once before chemotherapy, alongside a 5-HT3 blocker and dexamethasone, to prevent nausea and vomiting in the days after treatment.
Telotristat ethyl (Xermelo) is a tablet that cuts the serotonin that neuroendocrine tumours pour out, easing the relentless diarrhoea of carcinoid syndrome when somatostatin analogue injections are not enough.